<p>Fennec Pharmaceuticals（纳斯达克代码：FENC - 获取免费报告）的股票在周一的研究报告中被 Wedbush 的股票分析师重新给予了 “跑赢大盘” 的评级，RTT News 报道。他们目前对该股票的目标价为 13.00 美元。Wedbush 的目标价显示出相较于公司之前收盘价 112.77% 的潜在上涨空间。</p>
<p>获取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
<p>其他几位分析师也对 FENC 发布了报告。HC Wainwright 在 12 月 17 日的研究报告中重申了对 Fennec Pharmaceuticals 的 “买入” 评级，并给出了 13.00 美元的目标价。Stephens 在 11 月 18 日的研究报告中将 Fennec Pharmaceuticals 的评级上调至 “强力买入”。</p>
<p><strong>查看我们对 Fennec Pharmaceuticals 的最新股票分析</strong></p>
<h2>Fennec Pharmaceuticals 股票表现</h2>
<p>周一，纳斯达克代码：FENC 的股票下跌 0.77 美元，报 6.11 美元。该股票的交易量为 187,467 股，而其平均交易量为 111,607 股。Fennec Pharmaceuticals 的 1 年最低价为 3.96 美元，1 年最高价为 11.49 美元。该公司的 50 日简单移动平均线为 6.39 美元，200 日简单移动平均线为 5.61 美元。该股票的市值为 1.684 亿美元，市盈率为-61.09，贝塔值为 0.36。</p>
<p>Fennec Pharmaceuticals（纳斯达克代码：FENC - 获取免费报告）最后一次公布财报是在 3 月 10 日。该公司报告本季度每股收益（EPS）为-0.06 美元，低于市场共识预期的 0.56 美元，差距为 0.62 美元。Fennec Pharmaceuticals 的净利润率为-2.30%，股本回报率为-53.38%。股票研究分析师预测 Fennec Pharmaceuticals 在当前年度将发布-0.11 美元的每股收益。</p>
<h2>内部人士下注</h2>
<p>在相关消息中，董事 Rosty Raykov 在 3 月 5 日的交易中出售了 10,000 股公司的股票。该股票以平均价格 6.79 美元出售，总价值为 67,900.00 美元。交易完成后，该董事现在直接持有 68,725 股公司股票，价值约为 466,642.75 美元。此次交易使其持股减少了 12.70%。该出售在与证券交易委员会的法律文件中披露，该文件可通过 SEC 网站访问。内部人士在上个季度共出售了 31,186 股公司股票，价值 203,389 美元。公司内部人士持有公司股票的 10.98%。</p>
<h2>机构投资者对 Fennec Pharmaceuticals 的看法</h2>
<p>最近几家对冲基金增加或减少了对 FENC 的持股。Pinnacle Wealth Planning Services Inc.在第四季度购买了 Fennec Pharmaceuticals 的新股份，价值 97,000 美元。美国银行在第四季度将其在 Fennec Pharmaceuticals 的持股增加了 32.1%。美国银行现在持有 35,827 股公司股票，价值 226,000 美元，此前在该期间又购买了 8,703 股。法国巴黎银行金融市场在第四季度将其在 Fennec Pharmaceuticals 的持股增加了 11.5%。法国巴黎银行金融市场现在持有 44,626 股公司股票，价值 282,000 美元，此前在该期间又购买了 4,610 股。Solas Capital Management LLC 在第四季度将其在 Fennec Pharmaceuticals 的持股增加了 17.0%。Solas Capital Management LLC 现在持有 2,250,919 股公司股票，价值 14,226,000 美元，此前在上个季度又购买了 327,383 股。最后，MetLife Investment Management LLC 在第四季度购买了 Fennec Pharmaceuticals 的新股份，价值约 99,000 美元。机构投资者持有公司股票的 55.51%。</p>
<h2>关于 Fennec Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Fennec Pharmaceuticals Inc 是一家生物制药公司，开发用于治疗美国癌症的产品候选药物。其主要产品候选药物是硫代硫酸钠，已完成用于预防儿童顺铂引起的听力损失或耳毒性的第三阶段临床试验。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Fennec Pharmaceuticals 更好</li>
<li>股票交易术语 - 每位投资者都需要了解的股票术语</li>
<li>当通货膨胀上升时如何保护您的投资组合</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>3 只在 2025 年逆势而上并蓬勃发展的科技股</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>尽管面临挑战，诺和诺德计划击败 GLP-1 竞争对手</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Fennec Pharmaceuticals 吗？</h2>
<p>在您考虑 Fennec Pharmaceuticals 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买...而 Fennec Pharmaceuticals 并不在名单上。</p>
<p>虽然 Fennec Pharmaceuticals 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

FENC

<p>Wedbush 重申了对 Fennec Pharmaceuticals（NASDAQ:FENC）的 “跑赢大盘” 评级，目标价为 13.00 美元，意味着相较于其前一交易日收盘价有 112.77% 的潜在上涨空间。该股票交易价格下跌至 6.11 美元，市值为 1.684 亿美元。分析师预测当前年度每股收益为-0.11。机构投资者持有该公司 55.51% 的股份，最近的内部交易显示董事 Rosty Raykov 的持股有所减少。Fennec Pharmaceuticals 专注于开发癌症治疗方案，其主要候选药物旨在预防儿童听力损失</p>

<p>Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report)'s stock had its &#34;outperform&#34; rating reissued by stock analysts at Wedbush in a research note issued on Monday,RTT News reports. They currently have a $13.00 price objective on the stock. Wedbush's target price points to a potential upside of 112.77% from the company's previous close.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals（纳斯达克代码：FENC - 获取免费报告）的股票在周一的研究报告中被 Wedbush 的股票分析师重新给予了 “跑赢大盘” 的评级，RTT News 报道。他们目前对该股票的目标价为 13.00 美元。Wedbush 的目标价显示出相较于公司之前收盘价 112.77% 的潜在上涨空间。</p>
</div><p>Get <strong>Fennec Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other analysts have also issued reports on FENC. HC Wainwright restated a &#34;buy&#34; rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th. Stephens upgraded Fennec Pharmaceuticals to a &#34;strong-buy&#34; rating in a research note on Monday, November 18th.</p>
<div class="lb-trans"><p>其他几位分析师也对 FENC 发布了报告。HC Wainwright 在 12 月 17 日的研究报告中重申了对 Fennec Pharmaceuticals 的 “买入” 评级，并给出了 13.00 美元的目标价。Stephens 在 11 月 18 日的研究报告中将 Fennec Pharmaceuticals 的评级上调至 “强力买入”。</p>
</div><p><strong>View Our Latest Stock Analysis on Fennec Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Fennec Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Fennec Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 股票表现</h2>
</div><p>NASDAQ:FENC traded down $0.77 on Monday, hitting $6.11. The stock had a trading volume of 187,467 shares, compared to its average volume of 111,607. Fennec Pharmaceuticals has a 1 year low of $3.96 and a 1 year high of $11.49. The firm's fifty day simple moving average is $6.39 and its two-hundred day simple moving average is $5.61. The stock has a market cap of $168.40 million, a P/E ratio of -61.09 and a beta of 0.36.</p>
<div class="lb-trans"><p>周一，纳斯达克代码：FENC 的股票下跌 0.77 美元，报 6.11 美元。该股票的交易量为 187,467 股，而其平均交易量为 111,607 股。Fennec Pharmaceuticals 的 1 年最低价为 3.96 美元，1 年最高价为 11.49 美元。该公司的 50 日简单移动平均线为 6.39 美元，200 日简单移动平均线为 5.61 美元。该股票的市值为 1.684 亿美元，市盈率为-61.09，贝塔值为 0.36。</p>
</div><p>Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.62). Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative return on equity of 53.38%. Equities research analysts predict that Fennec Pharmaceuticals will post -0.11 EPS for the current year.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals（纳斯达克代码：FENC - 获取免费报告）最后一次公布财报是在 3 月 10 日。该公司报告本季度每股收益（EPS）为-0.06 美元，低于市场共识预期的 0.56 美元，差距为 0.62 美元。Fennec Pharmaceuticals 的净利润率为-2.30%，股本回报率为-53.38%。股票研究分析师预测 Fennec Pharmaceuticals 在当前年度将发布-0.11 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In related news, Director Rosty Raykov sold 10,000 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $6.79, for a total value of $67,900.00. Following the completion of the transaction, the director now directly owns 68,725 shares in the company, valued at approximately $466,642.75. The trade was a 12.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 31,186 shares of company stock valued at $203,389 in the last quarter. Corporate insiders own 10.98% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Rosty Raykov 在 3 月 5 日的交易中出售了 10,000 股公司的股票。该股票以平均价格 6.79 美元出售，总价值为 67,900.00 美元。交易完成后，该董事现在直接持有 68,725 股公司股票，价值约为 466,642.75 美元。此次交易使其持股减少了 12.70%。该出售在与证券交易委员会的法律文件中披露，该文件可通过 SEC 网站访问。内部人士在上个季度共出售了 31,186 股公司股票，价值 203,389 美元。公司内部人士持有公司股票的 10.98%。</p>
</div><h2>Institutional Investors Weigh In On Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Fennec Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in FENC. Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Fennec Pharmaceuticals in the 4th quarter valued at $97,000. Bank of America Corp DE boosted its position in Fennec Pharmaceuticals by 32.1% during the fourth quarter. Bank of America Corp DE now owns 35,827 shares of the company's stock valued at $226,000 after buying an additional 8,703 shares during the period. BNP Paribas Financial Markets boosted its position in Fennec Pharmaceuticals by 11.5% during the fourth quarter. BNP Paribas Financial Markets now owns 44,626 shares of the company's stock valued at $282,000 after buying an additional 4,610 shares during the period. Solas Capital Management LLC grew its stake in shares of Fennec Pharmaceuticals by 17.0% during the fourth quarter. Solas Capital Management LLC now owns 2,250,919 shares of the company's stock valued at $14,226,000 after buying an additional 327,383 shares during the last quarter. Finally, MetLife Investment Management LLC purchased a new position in shares of Fennec Pharmaceuticals in the fourth quarter worth about $99,000. Institutional investors own 55.51% of the company's stock.</p>
<div class="lb-trans"><p>最近几家对冲基金增加或减少了对 FENC 的持股。Pinnacle Wealth Planning Services Inc.在第四季度购买了 Fennec Pharmaceuticals 的新股份，价值 97,000 美元。美国银行在第四季度将其在 Fennec Pharmaceuticals 的持股增加了 32.1%。美国银行现在持有 35,827 股公司股票，价值 226,000 美元，此前在该期间又购买了 8,703 股。法国巴黎银行金融市场在第四季度将其在 Fennec Pharmaceuticals 的持股增加了 11.5%。法国巴黎银行金融市场现在持有 44,626 股公司股票，价值 282,000 美元，此前在该期间又购买了 4,610 股。Solas Capital Management LLC 在第四季度将其在 Fennec Pharmaceuticals 的持股增加了 17.0%。Solas Capital Management LLC 现在持有 2,250,919 股公司股票，价值 14,226,000 美元，此前在上个季度又购买了 327,383 股。最后，MetLife Investment Management LLC 在第四季度购买了 Fennec Pharmaceuticals 的新股份，价值约 99,000 美元。机构投资者持有公司股票的 55.51%。</p>
</div><h2>About Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Fennec Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc 是一家生物制药公司，开发用于治疗美国癌症的产品候选药物。其主要产品候选药物是硫代硫酸钠，已完成用于预防儿童顺铂引起的听力损失或耳毒性的第三阶段临床试验。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Fennec Pharmaceuticals</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>How to Protect Your Portfolio When Inflation Is Rising</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>3 Tech Stocks Defying Sector Weakness and Thriving in 2025</li>
<li>High Flyers: 3 Natural Gas Stocks for March 2022</li>
<li>Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Fennec Pharmaceuticals 更好</li>
<li>股票交易术语 - 每位投资者都需要了解的股票术语</li>
<li>当通货膨胀上升时如何保护您的投资组合</li>
<li>股票评级和推荐：理解分析师评级</li>
<li>3 只在 2025 年逆势而上并蓬勃发展的科技股</li>
<li>高飞者：2022 年 3 月的 3 只天然气股票</li>
<li>尽管面临挑战，诺和诺德计划击败 GLP-1 竞争对手</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Fennec Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Fennec Pharmaceuticals 吗？</h2>
</div><p>Before you consider Fennec Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Fennec Pharmaceuticals 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买...而 Fennec Pharmaceuticals 并不在名单上。</p>
</div><p>While Fennec Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Fennec Pharmaceuticals 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Fennec Pharmaceuticals (NASDAQ:FENC) 获得了 Wedbush 的优于大盘评级